Log In
Print this Print this

TransCon Hydrogel anti-VEGF Depot, TransCon ranibizumab

  Manage Alerts
Collapse Summary General Information
Company Ascendis Pharma A/S
DescriptionHalf-yearly intravitreal administration of anti-VEGF injection
Molecular Target Vascular endothelial growth factor (VEGF)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat age-related macular degeneration (AMD)
Regulatory Designation
PartnerGenentech Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today